Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 1/20 | 0.59 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CASP3 | P42574 | 1/20 | 0.57 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.57 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.53 |
| ▸ | MTHFD1 | P11586 | 1/20 | 0.52 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.52 |
| ▸ | SCN1A | P35498 | 2/20 | 0.51 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.51 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17869370 | 0.92 | ALDH1A1 (0.55) | SRD5A1SRD5A2ALDH1A1LMNACASP3 | |
| SCHEMBL22664149 | 0.92 | ALDH1A1 (0.55) | SRD5A1SRD5A2ALDH1A1LMNACASP3 | |
| SCHEMBL1480727 | 0.87 | HRH3 (0.56) | SRD5A1LMNAHRH3SMN1; SMN2SCN1A | |
| SCHEMBL18871654 | 0.86 | PARP10 (0.69) | SENP8SENP6HRH3SMN1; SMN2SCN1A | |
| SCHEMBL24244897 | 0.85 | L3MBTL1 (0.53) | SRD5A1SRD5A2ALDH1A1LMNACASP3 | |
| SCHEMBL26815710 | 0.85 | RXRB (0.53) | SMN1; SMN2SCN1ASCN2ASCN3A | |
| SCHEMBL3458256 | 0.84 | SCN1A (0.56) | LMNAHRH3SMN1; SMN2EPHX2SCN1A | |
| SCHEMBL1977190 | 0.84 | ALDH1A1 (0.70) | SRD5A1SRD5A2ALDH1A1LMNACASP3 | |
| SCHEMBL4682743 | 0.84 | SRD5A1 (0.67) | SRD5A1SRD5A2ALDH1A1LMNACASP3 | |
| SCHEMBL4237677 | 0.83 | SRD5A1 (0.55) | SRD5A1SRD5A2ALDH1A1LMNACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-20220041559-A1 | BENZO-AND PYRIDO-PYRAZOLES AS PROTEIN KINASE INHIBITORS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2022-02-10 | — | — | US | disclosed |
| EP-3623372-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-03-18 | — | — | EP | disclosed |
| EP-3240791-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2019-11-06 | — | — | EP | disclosed |
| EP-2266987-B1 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-05-17 | — | — | EP | disclosed |
| EP-1575954-B1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-08-03 | — | — | EP | disclosed |
| US-8785448-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-07-22 | — | — | US | disclosed |
| US-20130344031-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-12-26 | — | — | US | disclosed |
| US-8557845-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-10-15 | — | — | US | disclosed |
| US-8557857-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-10-15 | — | — | US | disclosed |
| US-7407971-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2008-08-05 | — | — | US | disclosed |
| US-7232825-B2 | Phenylaminopyrimidine derivatives and methods of use | CHEN GUOQING P | 2007-06-19 | — | — | US | disclosed |
| US-7232825-B2 | Phenylaminopyrimidine derivatives and methods of use | CHEN GUOQING P | 2007-06-19 | — | — | US | disclosed |
| US-20070004705-A1 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-01-04 | — | — | US | disclosed |
| EP-1575954-A2 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004056827-A2 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2004-07-08 | — | — | WO | disclosed |
| US-20030153604-A1 | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds | AVENTIS PHARMACEUTICALS INC. | 2003-08-14 | — | — | US | disclosed |
| US-6541505-B1 | Inhibiting the activity of Factor Xa; treating a disease state associated with a physiologically detrimental excess amount of thrombin. | AVENTIS PHARMACEUTICALS INC. | 2003-04-01 | — | — | US | disclosed |
| EP-1140901-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039087-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004705-A1 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | CCNI, CDK1, CDK2 | SRD5A1 1434/4885SRD5A2 2270/4885ALDH1A1 1596/4885 |
| US-20130344031-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | CCNI, CDK1, CDK2 | SRD5A1 1434/4885SRD5A2 2270/4885ALDH1A1 1596/4885 |
| US-20220041559-A1 | BENZO-AND PYRIDO-PYRAZOLES AS PROTEIN KINASE INHIBITORS | PDXK, MAP4K2, PLK2 | SRD5A1 4264/4885SRD5A2 4496/4885ALDH1A1 2514/4885 |
| US-20030153604-A1 | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds | SERPINC1, F2, F11 | SRD5A1 615/4885SRD5A2 835/4885ALDH1A1 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.